绿叶制药(02186.HK)：中期股东应占溢利同比减少19.3%至3.13亿元

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) reported a revenue increase of 3.5% year-on-year to RMB 3.181 billion for the six months ending June 30, 2025, while shareholder profit decreased by 19.3% to RMB 313 million [1] Financial Performance - Revenue increased by 3.5% to RMB 3.181 billion [1] - Shareholder profit decreased by 19.3% to RMB 313 million [1] - EBITDA increased by 4.2% to RMB 1.204 billion [1] - Earnings per share stood at RMB 0.0832 [1]